initiating prenatal care in the first trimester. Uninsurance was also associated with an 18% and 7% increased risk of severe preterm delivery (<28 weeks) and low birth weight, respectively. CONCLUSION: Access to insurance prior to conception is associated with earlier initiation of prenatal care. Many screening and risk reducing interventions (such as genetic screening, teratogenic and environmental exposure avoidance, preterm birth risk factors), which are routinely performed in the first trimester, may be missed or delayed with later initiation of prenatal care. Future studies should focus how changes in preconception insurance coverage affect initiation of prenatal care and further explore the causal links between this association.
OBJECTIVE: Standard sterile speculum exam (SSE) and rapid pointof-care (POC) immunoassays are testing modalities available for PROM diagnosis used in hospitals nationwide. We aimed to compare costs of POC immunoassay to SSE strategy for PROM diagnosis in a general obstetric (OB) population (>34 weeks' gestation). STUDY DESIGN: We constructed a decision analytic model to compare SSE and POC immunoassay for PROM diagnosis from a health care institution perspective during an OB triage visit. Since the diagnostic performance of the tests is equivalent, we performed a cost-minimization analysis. We assumed POC immunoassay would yield a positive or negative result with possible additional SSE exam, whereas SSE strategy could generate a positive, negative or equivocal result, the latter of which led to additional testing and time in OB triage. We assumed POC would save 15 minutes compared to SSE, that equivocal testing would add 1 hour to evaluation, with $121 POC test cost, $200/hour cost in OB triage and SSE equivalent test rate of w30%. Model inputs for costs and probabilities were derived from the literature and local institutional data. Probabilistic analysis (PSA) was used to determine the probability that each strategy would be the lowest cost option over 10,000 Monte Carlo simulations. One-way and two-way sensitivity analyses were used to assess parameter uncertainty. RESULTS: PSA showed that the POC immunoassay strategy resulted in lower costs than SSE (mean difference -$47 [95% CI $(-)243, 30]) and was cost saving in 58% of simulations (see Table) . SSE with unequivocal results was the only clinical scenario where SSE strategy had lower costs ($419). One-way sensitivity analyses showed that POC was cost-saving if any of the following conditions were met: SSE test cost >$13, POC immunoassay test cost <$178, OB triage stay cost >$107/hour, >4.6 minutes were saved or the rate of equivocal SSE test was >14.2%. Two-way sensitivity analyses for test cost results are shown in our Figure. CONCLUSION: POC immunoassay is cost-saving in a general OB population presenting for PROM evaluation due in large part to time saved in the workup of equivocal SSE results. Which strategy is costsaving in practice will vary by institution depending on OB triage infrastructure, baseline cost for care, equivocal SSE test rate and POC immunoassay cost. Uniformed Services University of the Health Sciences, Bethesda, MD OBJECTIVE: Performance measures are widely used in healthcare, ranging from quality reporting, accountability, payment and monitoring of physicians and organizations. We sought to assess the validity and evidence for the Medicare Merit-based Incentive Payment System (MIPS) measures for obstetrics and gynecology. STUDY DESIGN: Using MIPS measures, we reviewed the 46 OB/GYN measures. A group of 4 obstetrician-gynecologists and maternal fetal medicine physicians assessed the validity of the metrics for importance, appropriate care, clinical evidence, specifications and feasibility. Measures were assessed using a 9-point scale (1-3 does not meet criteria; 4-6 meets some criteria; 7-9 meets criteria). Median scores were calculated, with measures considered valid with median rating of 7-9, not valid with median rating of 1-3, and 4-6 was uncertain. Microsoft Excel was used for analysis. RESULTS: The percentage of measures rated as uncertain validity was 43% (n¼20), with 56% rated as valid and no measures rated as non-valid. Valid measures had a range scores from 7-8.5, while measures of uncertain validity had a range of scores from 4.5-6.5. A higher percentage of measures endorsed by the national quality foundation (NQF) were considered valid (62%) compared to non-NQF endorsed measures (52% Massachusetts General Hospital, Boston, MA OBJECTIVE: Hospital policies restricting access to trial of labor after cesarean (TOLAC) are prevalent. We sought to quantify the proportion of TOLAC-eligible-women receiving prenatal care at a hospital with a TOLAC ban who opted to deliver at a hospital that offers TOLAC and to identify factors associated with this switch. STUDY DESIGN: This was a survey of TOLAC-eligible women with a single prior cesarean delivery receiving prenatal care at an urban hospital with a TOLAC ban. At a face-to-face interview conducted after 20 weeks gestation, participants were asked if they knew their hospital's TOLAC policy and how likely it was that they would switch hospitals to attempt a vaginal birth after cesarean (VBAC). Participants' delivery hospital and mode were obtained by medical record review. RESULTS: 48 women were interviewed; 69% (n¼33) were aware that their hospital had a TOLAC ban. 26 women (54%) said they were likely to switch hospitals to have a TOLAC, and 17 (35%) ultimately switched hospitals for delivery. (Figure) All but one who indicated she would not switch hospitals delivered via elective repeat cesarean delivery (ERCD), while over half of women (n¼16/26) who indicated an intention to switch hospitals did so, with a VBAC success rate of 93% (15/16). 44% of the study participants reported that their current prenatal care providers either definitely or probably thought that they should have a TOLAC, and, among these women, 62% ended up attempting VBAC. (p¼0.002). All 10 women who incorrectly thought that TOLAC was allowed delivered elsewhere; those aware of the TOLAC ban were less likely to switch. (Table) . In a multivariable logistic regression model, variables that were highly associated with transferring care included race/ethnicity other than Latina (aOR 25.2, p¼0.002), being unaware of the TOLAC ban (aOR 19.8, p¼0.001) , and perceiving that a close friend/relative preferred TOLAC (aOR 17.3, p¼0.014). CONCLUSION: At this urban hospital with a TOLAC ban, more than 1/ 3 of women with a prior CD switched hospitals to undergo TOLAC. Facilitating referral to a hospital that allows TOLAC would likely benefit many women with a prior CD whose current hospital has a TOLAC ban.
